Please login to the form below

Not currently logged in
Email:
Password:

Empliciti

This page shows the latest Empliciti news and features for those working in and with pharma, biotech and healthcare.

Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

oncology. BMS also scored a hit in the crowded field of multiple myeloma, with its Empliciti extending progression free survival in relapsing and remitting patients.

Latest news

  • FDA clears first-line use for J&J FDA clears first-line use for J&J

    Market research firm Persistence reckons Darzalex and another therapeutic antibody – Roche’s Empliciti (elotuzumab) – which “will not only provide a new treatment option for multiple myeloma patients, but they will also

  • FDA clears first-line use for J&J’s myeloma drug Darzalex FDA clears first-line use for J&J’s myeloma drug Darzalex

    Market research firm Persistence reckons Darzalex and another therapeutic antibody – Roche’s Empliciti (elotuzumab) – which “will not only provide a new treatment option for multiple myeloma patients, but they will also

  • AbbVie's PARP inhibitor veliparib fails to deliver AbbVie's PARP inhibitor veliparib fails to deliver

    AbbVie will draw comfort from its stake in three fast-growing blood cancer drugs - Imbruvica (ibrutinib), Venclexta (venetoclax) and Empliciti (elotuzumab) - and several mid-stage candidates including antibody drug conjugates (ADCs)

  • Amgen's Kyprolis tops Velcade in myeloma trial Amgen's Kyprolis tops Velcade in myeloma trial

    Multiple myeloma is becoming increasingly competitive, however, thanks to new launches such as Bristol-Myers Squibb's Empliciti (elotuzumab), Novartis' Farydak (panobinostat) and Johnson &Johnson's Darzalex (daratumumab).

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    Takeda's orally-active proteasome inhibitor Ninlaro (ixazomib), Novartis' HDAC inhibitor Farydak (panobinostat) and Bristol-Myers Squibb's SLAMF7 inhibitor Empliciti (elotuzumab) are all jostling for market share with Darzalex at

More from news
Approximately 6 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics